NASDAQ:KRTX Karuna Therapeutics (KRTX) Stock Price, News & Analysis → 8,788% Return Predicted For THIS Crypto (already up 40% in 6 months) (From Paradigm Press) (Ad) Free KRTX Stock Alerts $329.83 0.00 (0.00%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$329.83▼$329.8350-Day Range$313.42▼$329.8352-Week Range$158.38▼$329.99VolumeN/AAverage Volume572,350 shsMarket Capitalization$12.60 billionP/E RatioN/ADividend YieldN/APrice Target$293.92 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Karuna Therapeutics alerts: Email Address Karuna Therapeutics MarketRank™ Stock AnalysisAnalyst RatingHold2.38 Rating ScoreUpside/Downside10.9% Downside$293.92 Price TargetShort InterestHealthy5.16% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.56Based on 23 Articles This WeekInsider TradingSelling Shares$7.92 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($11.96) to ($7.31) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.34 out of 5 starsMedical Sector775th out of 946 stocksPharmaceutical Preparations Industry362nd out of 435 stocks 2.2 Analyst's Opinion Consensus RatingKaruna Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.38, and is based on 6 buy ratings, 10 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $293.92, Karuna Therapeutics has a forecasted downside of 10.9% from its current price of $329.83.Amount of Analyst CoverageKaruna Therapeutics has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 4.0 Short Interest Percentage of Shares Shorted5.16% of the outstanding shares of Karuna Therapeutics have been sold short.Short Interest Ratio / Days to CoverKaruna Therapeutics has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Karuna Therapeutics has recently decreased by 6.64%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldKaruna Therapeutics does not currently pay a dividend.Dividend GrowthKaruna Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for KRTX. Previous Next 2.5 News and Social Media Coverage News SentimentKaruna Therapeutics has a news sentiment score of 0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 23 news articles for Karuna Therapeutics this week, compared to 5 articles on an average week.Search InterestOnly 2 people have searched for KRTX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows2 people have added Karuna Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Karuna Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,924,500.00 in company stock.Percentage Held by Insiders13.20% of the stock of Karuna Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Karuna Therapeutics are expected to grow in the coming year, from ($11.96) to ($7.31) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Karuna Therapeutics is -28.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Karuna Therapeutics is -28.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKaruna Therapeutics has a P/B Ratio of 9.92. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Colonial MetalsCentral Bank Gold Heist In ProgressWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.That's why we have released our Free Precious Metals Investment Guide. About Karuna Therapeutics Stock (NASDAQ:KRTX)Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate includes KarXT, an oral modulator of muscarinic receptors for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of various peripheral tissues and dementia-related psychosis, including Alzheimer's disease. The company also focuses on developing other muscarinic-targeted drug candidates; and intends to develop lead candidature TRPC4/5 and KAR-2618 for the treatment of depressive disorder. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company, and Zai Lab (Shanghai) Co., Ltd; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.Read More KRTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart KRTX Stock News HeadlinesMarch 12, 2024 | insidertrades.comKaruna Therapeutics, Inc. (NASDAQ:KRTX) Insider Sells $1,591,700.00 in StockMarch 18, 2024 | americanbankingnews.comEquities Analysts Offer Predictions for Karuna Therapeutics, Inc.'s Q1 2024 Earnings (NASDAQ:KRTX)March 19, 2024 | InvestorPlace (Ad)They said crypto was dead. It went up 100X.Bitcoin’s haters are out again. Despite the price doubling in the last six months alone… That hasn’t stopped the experts from piling on. Warren Buffett’s right-hand man Charlie Munger called crypto investors “idiots” in one of his last interviews. JPMorgan CEO Jamie Dimon, recently called Bitcoin a “pet rock” and “a hyped-up fraud.” But when it comes to cryptos, these are exactly the people you shouldn’t listen to. They’ve predicted crypto’s demise for years.March 16, 2024 | americanbankingnews.comKaruna Therapeutics (NASDAQ:KRTX) Shares Gap Up to $321.98March 16, 2024 | americanbankingnews.comKaruna Therapeutics, Inc. (NASDAQ:KRTX) Expected to Post FY2026 Earnings of ($4.32) Per ShareMarch 15, 2024 | finance.yahoo.comLoss-Making Karuna Therapeutics, Inc. (NASDAQ:KRTX) Expected To Breakeven In The Medium-TermMarch 15, 2024 | ca.finance.yahoo.comKRTX May 2024 210.000 callMarch 14, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Karuna Therapeutics (KRTX) and Cannabist Company Holdings (OtherCBSTF)March 19, 2024 | Banyan Hill Publishing (Ad)AI Cracks Open Largest Untapped Energy Reserve on EarthThis orb represents the largest untapped energy source in the world… And although this energy resource is unknown by 99% of the public… It makes gas, coal, oil, wind, hydropower, solar, fusion… March 12, 2024 | americanbankingnews.comKaruna Therapeutics, Inc. (NASDAQ:KRTX) Insider Stephen K. Brannan Sells 5,000 SharesMarch 11, 2024 | americanbankingnews.comFY2024 EPS Estimates for Karuna Therapeutics, Inc. Cut by Cantor Fitzgerald (NASDAQ:KRTX)March 10, 2024 | americanbankingnews.comKaruna Therapeutics, Inc. (NASDAQ:KRTX) Given Average Recommendation of "Hold" by BrokeragesMarch 4, 2024 | finance.yahoo.comBronte Amalthea Fund Incurred Loss in Karuna Therapeutics (KRTX) Short PositionFebruary 26, 2024 | msn.comKaruna Therapeutics drops on no apparent news amid deal with Bristol-Myers SquibbFebruary 23, 2024 | benzinga.com1KRTX : Karuna Therapeutics: Q4 Earnings InsightsFebruary 22, 2024 | msn.comKaruna Therapeutics GAAP EPS of -$3.01 misses by $0.29February 22, 2024 | finance.yahoo.comKaruna Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides General Business UpdateFebruary 22, 2024 | businesswire.comKaruna Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides General Business UpdateFebruary 21, 2024 | seekingalpha.comBronte Capital - Karuna Therapeutics: A Rare Mistake With A Natural Test Of ProcessFebruary 18, 2024 | seekingalpha.comKaruna Therapeutics: Getting Sold ShortFebruary 17, 2024 | finance.yahoo.comKRTX Mar 2024 320.000 callFebruary 17, 2024 | finance.yahoo.comKRTX Mar 2024 260.000 putFebruary 17, 2024 | finance.yahoo.comKRTX Mar 2024 330.000 callFebruary 17, 2024 | finance.yahoo.comKRTX Mar 2024 280.000 putFebruary 14, 2024 | businesswire.comKARUNA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Karuna Therapeutics, Inc. - KRTXJanuary 31, 2024 | finance.yahoo.comKaruna Therapeutics (KRTX) Rose on Acquisition AnnouncementJanuary 29, 2024 | msn.comKaruna’s KarXT tops Evaluate’s most anticipated drug listSee More Headlines Receive KRTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Karuna Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/22/2024Today3/19/2024Next Earnings (Estimated)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:KRTX CUSIPN/A CIK1771917 Webkarunatx.com Phone(857) 449-2244FaxN/AEmployees339Year FoundedN/APrice Target and Rating Average Stock Price Target$293.92 High Stock Price Target$330.00 Low Stock Price Target$225.00 Potential Upside/Downside-10.9%Consensus RatingHold Rating Score (0-4)2.38 Research Coverage16 Analysts Profitability EPS (Most Recent Fiscal Year)($11.72) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-433,680,000.00 Net MarginsN/A Pretax Margin-66,209.48% Return on Equity-31.63% Return on Assets-30.38% Debt Debt-to-Equity RatioN/A Current Ratio19.31 Quick Ratio19.31 Sales & Book Value Annual Sales$650,000.00 Price / Sales19,383.86 Cash FlowN/A Price / Cash FlowN/A Book Value$33.24 per share Price / Book9.92Miscellaneous Outstanding Shares38,200,000Free Float33,157,000Market Cap$12.60 billion OptionableOptionable Beta1.18 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesDr. Andrew Craig Miller Ph.D. (Age 42)Founder and President of Research & Development Comp: $835.4kDr. Stephen K. Brannan (Age 68)Chief Medical Officer Comp: $751.75kMr. William Meury (Age 56)President, CEO & Director Mr. Jason Parker BrownChief Financial OfficerMs. Alexis SmithVice President of Corporate Affairs & Investor RelationsMs. Mia Kelley J.D.General CounselMr. Frank TruslowSenior Vice President of Corporate DevelopmentMr. Jonathan RosinChief Human Resources OfficerDr. Alan BreierChair of Scientific Advisory Board & Chief Clinical AdvisorDr. Ronald N. Marcus M.D. (Age 66)Senior Vice President of Medical More ExecutivesKey CompetitorsDr. Reddy's LaboratoriesNYSE:RDYUnited TherapeuticsNASDAQ:UTHRSarepta TherapeuticsNASDAQ:SRPTLegend BiotechNASDAQ:LEGNViatrisNASDAQ:VTRSView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 21,201 shares on 3/11/2024Ownership: 8.453%Stephen K BrannanSold 5,000 sharesTotal: $1.59 M ($318.34/share)Wellington Management Group LLPSold 151,462 shares on 3/5/2024Ownership: 2.973%Goldman Sachs Group Inc.Bought 166,001 shares on 3/1/2024Ownership: 0.528%Virtu Financial LLCBought 13,073 shares on 2/26/2024Ownership: 0.034%View All Insider TransactionsView All Institutional Transactions KRTX Stock Analysis - Frequently Asked Questions Should I buy or sell Karuna Therapeutics stock right now? 16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Karuna Therapeutics in the last twelve months. There are currently 10 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" KRTX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in KRTX, but not buy additional shares or sell existing shares. View KRTX analyst ratings or view top-rated stocks. What is Karuna Therapeutics' stock price target for 2024? 16 analysts have issued 1 year price objectives for Karuna Therapeutics' shares. Their KRTX share price targets range from $225.00 to $330.00. On average, they anticipate the company's share price to reach $293.92 in the next twelve months. This suggests that the stock has a possible downside of 10.9%. View analysts price targets for KRTX or view top-rated stocks among Wall Street analysts. How have KRTX shares performed in 2024? Karuna Therapeutics' stock was trading at $316.51 at the beginning of 2024. Since then, KRTX stock has increased by 4.2% and is now trading at $329.83. View the best growth stocks for 2024 here. Are investors shorting Karuna Therapeutics? Karuna Therapeutics saw a decline in short interest during the month of February. As of February 29th, there was short interest totaling 1,970,000 shares, a decline of 6.6% from the February 14th total of 2,110,000 shares. Based on an average daily volume of 858,500 shares, the short-interest ratio is currently 2.3 days. View Karuna Therapeutics' Short Interest. When is Karuna Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our KRTX earnings forecast. How were Karuna Therapeutics' earnings last quarter? Karuna Therapeutics, Inc. (NASDAQ:KRTX) posted its quarterly earnings data on Thursday, February, 22nd. The company reported ($3.01) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.65) by $0.36. The company's quarterly revenue was down 100.0% on a year-over-year basis. During the same period in the previous year, the business earned ($2.22) EPS. What ETFs hold Karuna Therapeutics' stock? ETFs with the largest weight of Karuna Therapeutics (NASDAQ:KRTX) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), Alpha Architect U.S. Quantitative Momentum ETF (QMOM), Principal Healthcare Innovators ETF (BTEC), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Invesco Nasdaq Biotechnology ETF (IBBQ) and Vanguard Russell 2000 Growth ETF (VTWG). What other stocks do shareholders of Karuna Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Karuna Therapeutics investors own include NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), AbbVie (ABBV), Pfizer (PFE), Alibaba Group (BABA), Johnson & Johnson (JNJ), AT&T (T), Target (TGT) and Walt Disney (DIS). When did Karuna Therapeutics IPO? (KRTX) raised $70 million in an initial public offering (IPO) on Friday, June 28th 2019. The company issued 4,400,000 shares at $15.00-$17.00 per share. Goldman Sachs, Citigroup and Wells Fargo Securities served as the underwriters for the IPO and Wedbush PacGrow was co-manager. Who are Karuna Therapeutics' major shareholders? Karuna Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Capital International Investors (11.20%), Vanguard Group Inc. (8.55%), Vanguard Group Inc. (8.45%), Price T Rowe Associates Inc. MD (5.20%), Wellington Management Group LLP (2.97%) and Brown Advisory Inc. (0.88%). Insiders that own company stock include Andrew Craig Miller, Atul Pande, James Healy, Jeffrey M Jonas, Laurie J Olson, Laurie J Olson, Stephen K Brannan, Steven M Paul and Troy A Ignelzi. View institutional ownership trends. How do I buy shares of Karuna Therapeutics? Shares of KRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:KRTX) was last updated on 3/19/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial Metals8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressLike Tiny Crypto Retirement FundsCrypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceStock-Picking AI Predicts #1 Stock of 2024AltimetrySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyThe world’s greatest investmentPorter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Karuna Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.